153 related articles for article (PubMed ID: 14583180)
1. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Ushiyama C; Osada S; Inoue T; Shimada N; Koide H
J Diabetes Complications; 2003; 17(6):349-54. PubMed ID: 14583180
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
3. Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans.
Nakamura T; Kawagoe Y; Matsuda T; Takahashi Y; Sekizuka K; Ebihara I; Koide H
Kidney Blood Press Res; 2003; 26(3):185-91. PubMed ID: 12886046
[TBL] [Abstract][Full Text] [Related]
4. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Utsumi K; Kawabe M; Hirama A; Ueda K; Kamada Y; Arii K; Komaba Y; Katsura K; Iino Y; Katayama Y
Clin Chim Acta; 2007 Feb; 377(1-2):198-200. PubMed ID: 17126824
[TBL] [Abstract][Full Text] [Related]
5. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease.
Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Koide H
Clin Nephrol; 2004 Jun; 61(6):429-33. PubMed ID: 15224807
[TBL] [Abstract][Full Text] [Related]
7. LDL apheresis in atherosclerotic disease with hyperlipidemia.
Naganuma S; Agishi T; Ota K
ASAIO J; 1992; 38(3):M436-9. PubMed ID: 1457897
[TBL] [Abstract][Full Text] [Related]
8. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms.
Mii S; Mori A; Sakata H; Nakayama M; Tsuruta H
Angiology; 1998 Mar; 49(3):175-80. PubMed ID: 9523539
[TBL] [Abstract][Full Text] [Related]
9. Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease.
Kamimura M; Matsuo M; Miyahara T; Kimura K; Matsumoto K; Nakaya T; Abe T; Akizawa T
Ther Apher; 2002 Dec; 6(6):467-70. PubMed ID: 12460413
[TBL] [Abstract][Full Text] [Related]
10. Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study.
Nakajima F; Morimoto S; Yurugi T; Amari Y; Kasuno Y; Fukui M; Furumatsu Y; Kitamura T
Int J Artif Organs; 2012 Nov; 35(11):981-5. PubMed ID: 23065872
[TBL] [Abstract][Full Text] [Related]
11. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment.
Inoue I; Takahashi K; Kikuchi C; Katayama S
Diabetes Care; 1996 Oct; 19(10):1103-7. PubMed ID: 8886556
[TBL] [Abstract][Full Text] [Related]
12. [Arteriosclerosis obliterans that was improved by LDL apheresis].
Suzuki H; Mutoh E; Kitagawa T; Kubota H; Takasugi Y
Hokkaido Igaku Zasshi; 1993 Jan; 68(1):126-31. PubMed ID: 8444401
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms.
Suzuki T; Sato Y; Niizuma S; Kushiro T; Tani S; Ishikawa K; Kajiwara N; Kanmatsuse K; Ikeda H; Takahashi M; Kojima S
J Clin Apher; 2007; 22(5):287-91. PubMed ID: 17610290
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
[TBL] [Abstract][Full Text] [Related]
15. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
[TBL] [Abstract][Full Text] [Related]
16. Analysis of protein absorbed by LDL column (Liposorber) with special reference to complement component factor D.
Oda O; Nagaya T; Ogawa H
Clin Chim Acta; 2004 Apr; 342(1-2):155-60. PubMed ID: 15026276
[TBL] [Abstract][Full Text] [Related]
17. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans.
Uno H; Ueki Y; Murashima J; Miyake S; Tominaga Y; Eguchi K; Yano K
Atherosclerosis; 1995 Jul; 116(1):93-102. PubMed ID: 7488336
[TBL] [Abstract][Full Text] [Related]
18. Minimal impact of low-density lipoprotein apheresis on vancomycin serum concentration: A case report.
Hiyama Y; Tomita T; Matsuo H
J Infect Chemother; 2024 Aug; 30(8):812-814. PubMed ID: 38316186
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits.
Yamamoto T; Yamashita T
Ther Apher; 1998 Feb; 2(1):25-30. PubMed ID: 10227785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
